Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 8/20 | 0.36 |
| ▸ | IDO1 | P14902 | 3/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1274115 | 1.00 | CES2 (0.38) | CES2CES1CA12CA1CA9 | |
| SCHEMBL31749211 | 0.87 | GBA1 (0.38) | GBA1 | |
| SCHEMBL16679663 | 0.87 | GBA1 (0.38) | GBA1 | |
| SCHEMBL16679665 | 0.87 | GBA1 (0.38) | GBA1 | |
| SCHEMBL16679135 | 0.86 | MAPK1 (0.32) | — | |
| SCHEMBL19822334 | 0.86 | GBA1 (0.37) | GBA1IDO1TDO2 | |
| SCHEMBL16679207 | 0.86 | GBA1 (0.37) | GBA1IDO1TDO2 | |
| SCHEMBL18793784 | 0.86 | GNRHR (0.33) | GBA1 | |
| SCHEMBL31749766 | 0.86 | GBA1 (0.37) | GBA1IDO1TDO2 | |
| SCHEMBL16679137 | 0.86 | MAPK1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326766-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2025106362-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4526300-A1 | RIPK1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20240025912-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025912-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025912-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023225041-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225041-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| US-11345678-B2 | Benzopyrazole compound used as RHO kinase inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20210371393-A1 | BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2021-12-02 | — | — | US | disclosed |
| EP-3782987-A1 | BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR | Medshine Discovery Inc. (CN) | 2021-02-24 | — | — | EP | disclosed |
| WO-2019201297-A1 | BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR | 南京明德新药研发有限公司 | 2019-10-24 | — | — | WO | disclosed |
| WO-2004064774-A2 | DNA ENCODING A HUMAN MELANIN CONCENTRATING HORMONE RECEPTOR (MCH1) AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20040038855-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2004-02-26 | — | — | US | disclosed |
| US-20030082623-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2003-05-01 | — | — | US | disclosed |
| US-20030077701-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2003-04-24 | — | — | US | disclosed |
| EP-1246847-A2 | DNA ENCODING A HUMAN MELANIN CONCENTRATING HORMONE RECEPTOR (MCH1) AND USES THEREOF | Synaptic Pharmaceutical Corporation (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2002002744-A2 | DNA ENCODING A HUMAN MELANIN CONCENTRATING HORMONE RECEPTOR (MCH1) AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082623-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | CES2 3073/4885CES1 3394/4885CA12 2846/4885 |
| US-20240025912-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | CES2 4320/4885CES1 1896/4885CA12 4235/4885 |
| US-20040038855-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | CES2 3334/4885CES1 3518/4885CA12 2642/4885 |
| US-20030077701-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | CES2 3073/4885CES1 3394/4885CA12 2846/4885 |
| US-20250326766-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | CES2 4256/4885CES1 1435/4885CA12 4284/4885 |
| US-11345678-B2 | Benzopyrazole compound used as RHO kinase inhibitor | ROCK1, ROCK2, CIT | CES2 4205/4885CES1 1510/4885CA12 4830/4885 |
| US-20210371393-A1 | BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR | ROCK1, ROCK2, CIT | CES2 4205/4885CES1 1510/4885CA12 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.